scholarly journals Economic burden of respiratory diseases and chronic obstructive pulmonary disease in Russian Federation, 2016

2019 ◽  
Vol 29 (2) ◽  
pp. 159-166 ◽  
Author(s):  
Anna V. Kontsevaya ◽  
Dinara K. Mukaneyeva ◽  
Yuliya A. Balanova ◽  
Mikhail B. Khudyakov ◽  
Oksana M. Drapkina
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Russian Federation ◽  
Emergency Care ◽  
Economic Burden ◽  
Respiratory Diseases ◽  
Premature Mortality ◽  
Economic Losses ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Care Costs

The aim of this study was to evaluate economic burden of respiratory diseases and chronic obstructive pulmonary disease (COPD) in Russian Federation (RF) in 2016 including direct costs and economic losses caused by decreased labor efficiency. Methods. The analysis included direct cost, such as healthcare expenses and disablement payout, and economic losses due to decreased labor efficiency by the reason of morbidity and premature mortality. Data of Federal State Statistics Service, annual State Statistical Reports, the State Guarantee Program of Free Medical Care for Citizens of Russian Federation, and statistical data on respiratory diseases and COPD were used. Costs of medical care (ambulatory, hospital, and emergency care) were calculated based on compulsory health insurance tariffs. The amount of disability benefits payments was calculated based on number of disabled persons in each group and the size of the disability benefit. Indirect costs (or economic losses) included losses from non-produced products due to premature mortality and disability of working-aged adults. Results. In 2016, there were 623,000 years of potential life lost (YPLL) due to respiratory diseases, mainly in males. Of this, 35% of deaths and 22% of YPLL were related to COPD. Healthcare costs for COPD treatment included hospital care costs (83.9%), ambulatory care costs (11.1%) and emergency care costs (5%). In 2016, the economic burden of COPD in Russian Federation reached 170.3 billion ₽, or 18.8% of all losses and expenditures from respiratory diseases. This is 0.2% of the gross domestic product (GDP) in the same year. Conclusion. The economic burden of COPD in Russia in 2016 was 170.3 billion ₽, or 0.2% of GDP. The burden of COPD predominantly consisted of economic losses caused by premature mortality of working-aged subjects. These data suggest that priority should be given to measures aimed at preventing the occurrence and slowing down the progression of this disease, probably by increase the investment in the prevention and treatment of COPD. Such measures could reduce clinical and economic consequences of COPD.

Medical and economic analysis of the consequences of expanding the drug supply program for patients with chronic obstructive pulmonary disease in the Russian Federation

2019 ◽  
pp. 53-61
Author(s):  
Andrei Georgievich Maliavin ◽  
Alana Viktorovna Dzanaeva ◽  
Maria Vladimirovna Avxentyeva ◽  
Sergei Lvovich Babak
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Russian Federation ◽  
Chronic Obstructive ◽  
Outpatient Basis ◽  
Basic Drug ◽  
Obstructive Pulmonary Disease ◽  
Basic Therapy ◽  
The Russian Federation ◽  
The Cost ◽  
Drug Provision

Purpose of the study. Healthcare budget impact analysis in the Russian Federation of providing adult patients with chronic obstructive pulmonary disease (COPD) with basic therapy for outpatient treatment. Material and methods. The hypothesis of reducing costs for the treatment of exacerbations of COPD was tested while providing all patients with basic therapy on an outpatient basis. The model calculates the direct medical costs of drug provision and treatment of exacerbations in patients with COPD in the current situation and when all patients with COPD are covered with basic therapy as part of a program of preferential drug provision. The simulation period is 1 year. The analysis does not take into account social losses associated with disability, payment of disability certificates, reduced labor productivity and mortality. Results. The cost of providing all patients with COPD with the recommended basic drug therapy on an outpatient basis is substantially offset by a decrease in the cost of treating exacerbations: drug costs should increase by 14.1 billion rubles compared with the current situation, while the cost of providing medical care to patients with exacerbations is reduced by 9.7 billion rubles. As a result, the difference in direct medical costs, or the necessary additional investments, is 4.4 billion rubles. The price of drugs used for basic therapy has the greatest impact on the size of the required additional investments. Conclusion. Providing all patients with COPD with the recommended basic drug therapy on an outpatient basis, we can expect a decrease in the number of moderate exacerbations per year by 14.7% and severe exacerbations by 31.2%. Taking into account not only medical, but also socio-economic costs can not only offset additional investments, but also demonstrate significant savings. When implementing a pilot project of preferential drug provision for patients with COPD in a specific region of the Russian Federation, it is possible to reduce the cost of purchasing medicines when forming a municipal order.

The Economic Burden of Chronic Obstructive Pulmonary Disease in Greece

2018 ◽  
Vol 17 (1) ◽  
pp. 111-121 ◽  
Author(s):  
Georgia Kourlaba ◽  
Georgios Hillas ◽  
Theodoros Vassilakopoulos ◽  
Nikos Maniadakis
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Economic Burden ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

Point-of-Care COPD Diagnostics: Biomarkers, Sampling, Paper-based Analytical Devices, and Perspectives

The Analyst ◽  
2022 ◽  
Author(s):  
Guozhen He ◽  
Tao Dong ◽  
Zhaochu Yang ◽  
Are Branstad ◽  
Lan Huang ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Early Diagnosis ◽  
Pulmonary Disease ◽  
Economic Burden ◽  
Point Of Care ◽  
Diagnosis And Treatment ◽  
Chronic Obstructive ◽  
Copd Exacerbation ◽  
Obstructive Pulmonary Disease ◽  
The Third

Chronic Obstructive pulmonary disease (COPD) has become the third leading causes of global death. Insufficiency in early-diagnosis and treatment of COPD, especially COPD exacerbation, leads to tremendous economic burden and...

Sign in / Sign up

Export Citation Format

Share Document